BACKGROUND/AIM: Cabazitaxel is recommended as first-line treatment after docetaxel for metastatic castration-resistant prostate cancer. However, the efficacy, adverse events and prognostic factors associated with cabazitaxel are unclear. PATIENTS AND METHODS: This single-centre retrospective study including 30 patients with CRPC treated with cabazitaxel between 2014 and 2020 investigated efficacy, outcomes and prognostic factors. RESULTS: Fourteen patients had visceral metastases. The median cabazitaxel dose was 20 mg/m2 The prostate-specific antigen response rate, time to prostate-specific antigen response, and overall survival were 13.3%, 3.48 months, and 7.92 months, respectively. The rates of grade 3 or more neutropenia and febrile neutropenia were 20% and 6.7%, respectively. By multivariate analysis, sarcopenia and visceral metastasis at the time of cabazitaxel initiation were independent and significant factors conferring a poor prognosis. CONCLUSION: The early introduction of cabazitaxel, prior to the development of sarcopenia and visceral metastasis, might contribute to improved prognosis in CRPC. Copyright
BACKGROUND/AIM: Cabazitaxel is recommended as first-line treatment after docetaxel for metastatic castration-resistant prostate cancer. However, the efficacy, adverse events and prognostic factors associated with cabazitaxel are unclear. PATIENTS AND METHODS: This single-centre retrospective study including 30 patients with CRPC treated with cabazitaxel between 2014 and 2020 investigated efficacy, outcomes and prognostic factors. RESULTS: Fourteen patients had visceral metastases. The median cabazitaxel dose was 20 mg/m2 The prostate-specific antigen response rate, time to prostate-specific antigen response, and overall survival were 13.3%, 3.48 months, and 7.92 months, respectively. The rates of grade 3 or more neutropenia and febrile neutropenia were 20% and 6.7%, respectively. By multivariate analysis, sarcopenia and visceral metastasis at the time of cabazitaxel initiation were independent and significant factors conferring a poor prognosis. CONCLUSION: The early introduction of cabazitaxel, prior to the development of sarcopenia and visceral metastasis, might contribute to improved prognosis in CRPC. Copyright
Authors: Tim Byers; Ermilo Barrera; Elizabeth T H Fontham; Lisa A Newman; Carolyn D Runowicz; Stephen F Sener; Michael J Thun; Sara Winborn; Richard C Wender Journal: Cancer Date: 2006-07-15 Impact factor: 6.860
Authors: Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger Journal: N Engl J Med Date: 2004-10-07 Impact factor: 91.245
Authors: Alexander Meisel; Stefanie von Felten; Deborah R Vogt; Heike Liewen; Ronald de Wit; Johann de Bono; Oliver Sartor; Frank Stenner-Liewen Journal: Eur J Cancer Date: 2016-01-30 Impact factor: 9.162
Authors: Ryan D Nipp; Georg Fuchs; Areej El-Jawahri; Julia Mario; Fabian M Troschel; Joseph A Greer; Emily R Gallagher; Vicki A Jackson; Avinash Kambadakone; Theodore S Hong; Jennifer S Temel; Florian J Fintelmann Journal: Oncologist Date: 2017-09-21